Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPBAR1 | Q8TDU6 | 5/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 3/20 | 1.00 |
| ▸ | VDR | P11473 | 3/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 1.00 |
| ▸ | EPHA2 | P29317 | 5/20 | 0.79 |
| ▸ | CASP7 | P55210 | 3/20 | 0.79 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.79 |
| ▸ | MAPT | P10636 | 3/20 | 0.79 |
| ▸ | USP2 | O75604 | 3/20 | 0.79 |
| ▸ | TP53 | P04637 | 2/20 | 0.79 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.79 |
| ▸ | BLM | P54132 | 2/20 | 0.79 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.79 |
| ▸ | LMNA | P02545 | 2/20 | 0.79 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.79 |
| ▸ | MDM4 | O15151 | 1/20 | 0.79 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.79 |
| ▸ | TSHR | P16473 | 1/20 | 0.79 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.79 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14269208 | 1.00 | GPBAR1 (1.00) | GPBAR1HIF1AVDRCYP2C9EPHA2 | |
| SCHEMBL14771006 | 1.00 | GPBAR1 (1.00) | GPBAR1HIF1AVDRCYP2C9EPHA2 | |
| SCHEMBL12205283 | 1.00 | GPBAR1 (1.00) | GPBAR1HIF1AVDRCYP2C9EPHA2 | |
| SCHEMBL12917358 | 1.00 | GPBAR1 (1.00) | GPBAR1HIF1AVDRCYP2C9EPHA2 | |
| SCHEMBL23776966 | 1.00 | GPBAR1 (1.00) | GPBAR1HIF1AVDRCYP2C9EPHA2 | |
| SCHEMBL21283583 | 1.00 | GPBAR1 (1.00) | GPBAR1HIF1AVDRCYP2C9EPHA2 | |
| SCHEMBL23285666 | 1.00 | GPBAR1 (1.00) | GPBAR1HIF1AVDRCYP2C9EPHA2 | |
| SCHEMBL14359988 | 1.00 | GPBAR1 (1.00) | GPBAR1HIF1AVDRCYP2C9EPHA2 | |
| SCHEMBL22079995 | 1.00 | GPBAR1 (1.00) | GPBAR1HIF1AVDRCYP2C9EPHA2 | |
| SCHEMBL12704721 | 1.00 | GPBAR1 (1.00) | GPBAR1HIF1AVDRCYP2C9EPHA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 199 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120081890-A | Preparation method of 7-ketolithocholic acid | 上海格苓凯生物科技有限公司 | 2025-06-03 | — | — | CN | claimed |
| CN-110023324-A | For treating the squalamine ester derivant of infection | 维克公司 | 2019-07-16 | — | — | CN | claimed |
| US-9939747-B2 | Developing agent and method for producing the same | TOSHIBA TEC KABUSHIKI KAISHA (JP) | 2018-04-10 | — | — | US | claimed |
| US-20170038698-A1 | DEVELOPING AGENT AND METHOD FOR PRODUCING THE SAME | TOSHIBA TEC KABUSHIKI KAISHA (JP) | 2017-02-09 | — | — | US | claimed |
| CN-1326461-A | Meiosis regulating compounds | NOVO NORDISK AS (DK) | 2001-12-12 | — | — | CN | claimed |
| US-20250319191-A1 | PHARMACEUTICAL COMPOSITION COMPRISING HYALURONIC ACID COMPLEX FOR PREVENTION OR TREATMENT OF SKIN DISEASE | UNIV AJOU IND ACADEMIC COOP FOUND (KR) | 2025-10-16 | — | — | US | disclosed |
| CN-120081890-A | Preparation method of 7-ketolithocholic acid | 上海格苓凯生物科技有限公司 | 2025-06-03 | — | — | CN | disclosed |
| EP-4371578-A1 | PHARMACEUTICAL COMPOSITION COMPRISING HYALURONIC ACID COMPLEX FOR PREVENTION OR TREATMENT OF SKIN DISEASE | Ajou University Industry-Academic Cooperation Foundation (KR) | 2024-05-22 | — | — | EP | disclosed |
| WO-2023085225-A1 | METHOD FOR MANUFACTURING RECYCLED RESIN COMPOSITION | 住友化学株式会社 | 2023-05-19 | — | — | WO | disclosed |
| US-11629166-B2 | Compound for treating clostridium difficile | ASTON UNIVERSITY (GB) | 2023-04-18 | — | — | US | disclosed |
| CN-115819491-A | Synthesis method of 7-ketolithocholic acid and ursodeoxycholic acid | 江苏佳尔科药业集团股份有限公司 | 2023-03-21 | — | — | CN | disclosed |
| US-11555099-B2 | Method for producing colorable material | TOSHIBA TEC KABUSHIKI KAISHA (JP) | 2023-01-17 | — | — | US | disclosed |
| US-5695738-A | Steroidal C-glycosides | GLYCOMED INCORPORATED (US) | 1997-12-09 | — | — | US | disclosed |
| US-5266566-A | Method of treating fungal infections using sterodial ester compounds | BRITISH TECHNOLOGY GROUP LIMITED | 1993-11-30 | — | — | US | disclosed |
| US-5158855-A | α-diazoacetoacetates and photosensitive resin compositions containing the same | HITACHI, LTD. (JP) | 1992-10-27 | — | — | US | disclosed |
| EP-0470995-A1 | USE OF STEROIDAL COMPOUNDS AS ANTI-FUNGAL AGENTS. | NAT RES DEV (GB) | 1992-02-19 | — | — | EP | disclosed |
| WO-1990013298-A1 | USE OF STEROIDAL COMPOUNDS AS ANTI-FUNGAL AGENTS | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1990-11-15 | — | — | WO | disclosed |
| US-4705847-A | Polycycloalkylidene-polycycloalkanes, epidioxy derivatives thereof and method of preparation | AKZO N.V. (NL) | 1987-11-10 | — | — | US | disclosed |
| US-4354972-A | Synthesis of steroids | KAISER EMIL T | 1982-10-19 | — | — | US | disclosed |
| US-4284577-A | Novel vitamin D3 derivative and process for preparing the same | Yamada, Sachiko (JP) | 1981-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11629166-B2 | Compound for treating clostridium difficile | DSTN, DAD1, DDOST | GPBAR1 77/4885HIF1A 3157/4885VDR 1537/4885 |
| US-20250319191-A1 | PHARMACEUTICAL COMPOSITION COMPRISING HYALURONIC ACID COMPLEX FOR PREVENTION OR TREATMENT OF SKIN DISEASE | TLR4, CD44, TLR1 | GPBAR1 1780/4885HIF1A 140/4885VDR 507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.